ProKidney Corp. (PROK) — Stock Valuation & Research

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the…

PROK key statistics

Price$1.05
Market cap$354.75M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range0.87-2.95
Beta1.9

Explore PROK's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.